<DOC>
	<DOCNO>NCT02027428</DOCNO>
	<brief_summary>Maintenance treatment advance stage squamous cell NSCLC</brief_summary>
	<brief_title>Safety Efficacy Study Abraxane Maintenance Treatment After Abraxane Plus Carboplatin 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer</brief_title>
	<detailed_description>Phase III , randomize , open-label , multi-center study nab-paclitaxel best supportive care ( BSC ) BSC alone maintenance treatment response SD nab-paclitaxel plus carboplatin induction subject stage IIB/IV squamous cell NSCLC .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<criteria>1 . Age ≥ 18 year age time sign Informed Consent Form . 2 . Understand voluntarily provide write consent Informed Consent Form prior conduct study related assessments/procedures . 3 . Able adhere study visit schedule protocol requirement Disease Specific 4 . Histologically cytologically confirm Stage IIIB IV squamous cell Non Small Cell Lung Cancer study entry . 5 . No current active malignancy require anticancer therapy . 6 . Radiographically document measurable disease study entry ( defined RECIST v1.1 criterion ) . 7 . No prior chemotherapy treatment metastatic disease study entry . Adjuvant chemotherapy permit provide cytotoxic chemotherapy complete 12 month prior start study without disease recurrence . 8 . Absolute neutrophil count ≥ 1500 cells/mm3 . 9 . Platelets ≥ 100,000 cells/mm3 . 10 . Hemoglobin ≥ 9 g/dL . 11 . Aspartate transaminase/serum glutamic oxaloacetic transaminase , alanine transaminase/serum glutamic pyruvic transaminase ≤ 2.5 × upper limit normal range ≤ 5.0 × upper limit normal range liver metastasis . 12 . Total bilirubin ≤ 1.5 × upper limit normal range except case Gilbert 's disease liver metastases . 13 . Creatinine ≤ 1.5 mg/dL . 14 . Expected survival &gt; 12 week Induction part study . 15 . Eastern Cooperative Oncology Group performance status 0 1 . 16 . For Maintenance part study , subject must receive least one dose nabpaclitaxel 4 cycle Induction Pregnancy 17 . Females childbearing potential [ define sexually mature woman ( 1 ) undergone hysterectomy ( surgical removal uterus ) bilateral oophorectomy ( surgical removal ovary ) ( 2 ) naturally postmenopausal least 24 consecutive month ( i.e. , menses time precede 24 consecutive month ) ] must : 1. agree take pregnancy test prior start study medication throughout study participation . 2. commit complete abstinence heterosexual contact , agree use medical doctorapproved contraception throughout study without interruption , receive study medication longer period require local regulation . Male subject must : 3. agree complete abstinence heterosexual contact use condom sexual contact female child bear potential receiving study medication within 6 month last dose study medication , even undergone successful vasectomy . 18 . Females must abstain breastfeeding study participation 3 month IP discontinuation . The presence follow exclude subject enrollment Induction Maintenance part study ( except specify study entry ) : 1 . Evidence active brain metastasis , include leptomeningeal involvement ( prior evidence brain metastasis permit treated stable therapy ≥ 4 week prior first dose study drug ) . 2 . Only evidence disease non measurable study entry . 3 . Preexisting peripheral neuropathy Grade 2 , 3 , 4 ( per Common Terminology Criteria Adverse Events v4.0 ) . 4 . Venous thromboembolism within 6 month prior sign Informed Consent Form . 5 . Current congestive heart failure ( New York Heart Association class IIIV ) . 6 . History follow within 6 month prior first administration study drug : myocardial infarction , severe/unstable angina pectoris , coronary/peripheral artery bypass graft , New York Heart Association ( NYHA ) Class IIIIV heart failure , uncontrolled hypertension , clinically significant cardiac dysrhythmia clinically significant ECG abnormality , cerebrovascular accident , transient ischemic attack , seizure disorder.7 . Treatment investigational product within 28 day prior sign Informed Consent Form . 8 . History allergy hypersensitivity nabpaclitaxel carboplatin . 9 . Currently enrol clinical protocol investigational trial involve administration experimental therapy and/or therapeutic device . 10 . Any clinically significant medical condition and/or organ dysfunction interfere administration therapy accord protocol . 11 . Subject malignancy within 5 year prior randomization . Exceptions include follow : squamous cell carcinoma skin , insitu carcinoma cervix , uteri , nonmelanomatous skin cancer , carcinoma situ breast , incidental histological finding prostate cancer ( TNM stage T1a T1b ) — treatment complete 6 month prior sign ICF . 12 . Subject receive radiotherapy ≤ 4 week limited field radiation palliation ≤ 2 week prior start IP , and/or ≥ 30 % bone marrow irradiate . Prior radiation therapy target lesion permit clear progression lesion since radiation complete . 13 . Pregnant nursing female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Nab-paclitaxel</keyword>
	<keyword>Albumin bound paclitaxel</keyword>
	<keyword>Taxanes</keyword>
	<keyword>Maintenance trial</keyword>
	<keyword>Celgene</keyword>
	<keyword>Abraxane</keyword>
	<keyword>ABI-007</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>Cancer Lung</keyword>
	<keyword>Carcinoma , Squamous Cell</keyword>
	<keyword>Lung Neoplasms</keyword>
	<keyword>Abound.sqm</keyword>
</DOC>